Key result
Dapagliflozin exposure was associated with significantly improved diastolic function (E/e' ratio 10.7 vs 12.8) and reduced NT-proBNP levels in patients with type 2 diabetes and heart failure with preserved ejection fraction.
Why the study?
Heart failure with preserved ejection fraction (HFpEF) has high morbidity and lacks effective treatment, prompting evaluation of the protective effects of dapagliflozin on diabetes-associated HFpEF.
Does dapagliflozin prevent the development of HFpEF in type 2 diabetes and what are the associated proteomic and metabolomic changes?
Observational (n=105)
No
Does dapagliflozin prevent the development of HFpEF in type 2 diabetes and what are the associated proteomic and metabolomic changes?
Answers are grounded in this paper and cite their sources.
Dapagliflozin prevents the development of HFpEF in diabetic rats through AMPK/mTOR pathway modulation and alters key metabolic pathways in humans with T2DM and HFpEF.
BACKGROUND: Heart failure with preserved ejection fraction (HFpEF) is a common disease with high morbidity and lacks effective treatment. We investigated the protective effects of the long-term application of the sodium-glucose cotransporter 2 inhibitor (SGLT2i) dapagliflozin on diabetes-associated HFpEF in a rat model. Serum proteomics and metabolomics analysis were also conducted in type 2 diabetic patients with HFpEF treated with dapagliflozin. METHODS: Male Zucker diabetic fatty (ZDF) rats were used as a model of diabetic cardiomyopathy. From weeks 16 to 28, animals were given a vehicle or dapagliflozin (1 mg/kg) once daily. Primary blood biochemistry indices, echocardiography, histopathology, and cardiac hemodynamics were determined during the study period. The key markers of myocardial fibrosis, nitro-oxidative stress, inflammation, apoptosis, autophagy, and AMPK/mTOR signaling were examined. Additionally, healthy controls and individuals with type 2 diabetes were enrolled and 16 serum samples from 4 groups were randomly selected. Serum proteome and metabolome changes after dapagliflozin treatment were analyzed in diabetic individuals with HFpEF. RESULTS: Dapagliflozin effectively prevented the development of HFpEF in rats with diabetes by mitigating nitro-oxidative stress, pro-inflammatory cytokines, myocardial hypertrophy, and fibrosis, reducing apoptosis, and restoring autophagy through AMPK activating and mTOR pathway repressing. Proteomics and metabolomics revealed that cholesterol and high-density lipoprotein particle metabolism, nicotinate and nicotinamide metabolism, arginine biosynthesis, and cAMP and peroxisome proliferator-activated receptor (PPAR) signaling are the major disturbed pathways in HFpEF patients treated with dapagliflozin. CONCLUSION: Long-term treatment with dapagliflozin significantly prevented the development of HFpEF in diabetic rats. Dapagliflozin could be a promising therapeutic strategy in managing HFpEF individuals with type 2 diabetes.
No takes yet. Share an insight, caveat, or question.
Feng et al. (2023) conducted an observational in Type 2 diabetes with heart failure with preserved ejection fraction (HFpEF) (n=105). Dapagliflozin vs. Type 2 diabetes with HFpEF not receiving dapagliflozin was evaluated on E/e' ratio (diastolic function) (p=<0.05). Dapagliflozin exposure was associated with significantly improved diastolic function (E/e' ratio 10.7 vs 12.8) and reduced NT-proBNP levels in patients with type 2 diabetes and heart failure with preserved ejection fraction.
Synapse has enriched 10 related papers. Consider them for comparative context: